Q1 Earnings Estimate for Rezolute Issued By HC Wainwright

Rezolute, Inc. (NASDAQ:RZLT) – Analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Rezolute in a research note issued to investors on Friday, February 13th. HC Wainwright analyst D. Tsao expects that the company will post earnings of ($0.08) per share for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Rezolute’s Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.11) EPS and FY2030 earnings at $0.35 EPS.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings data on Thursday, February 12th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.06).

Other equities research analysts also recently issued research reports about the stock. BTIG Research restated a “buy” rating and issued a $5.00 price objective on shares of Rezolute in a research note on Thursday, January 8th. Cantor Fitzgerald downgraded shares of Rezolute from an “overweight” rating to a “neutral” rating in a report on Thursday, December 11th. Citigroup cut shares of Rezolute from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 11th. JMP Securities set a $17.00 target price on Rezolute in a research report on Wednesday, October 29th. Finally, Citizens Jmp cut Rezolute from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 11th. Five investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.67.

Rezolute Stock Up 5.8%

Shares of NASDAQ RZLT opened at $3.84 on Monday. Rezolute has a 12 month low of $1.07 and a 12 month high of $11.46. The company has a market cap of $367.49 million, a P/E ratio of -4.13 and a beta of 0.46. The business’s 50 day moving average is $3.13 and its two-hundred day moving average is $6.53.

Insider Transactions at Rezolute

In related news, CFO Daron Evans purchased 40,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were acquired at an average price of $1.77 per share, with a total value of $70,800.00. Following the purchase, the chief financial officer directly owned 415,900 shares in the company, valued at $736,143. This represents a 10.64% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Nevan C. Elam purchased 32,000 shares of the stock in a transaction on Monday, December 15th. The stock was bought at an average price of $1.59 per share, for a total transaction of $50,880.00. Following the completion of the transaction, the chief executive officer directly owned 641,119 shares of the company’s stock, valued at approximately $1,019,379.21. This trade represents a 5.25% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have acquired 89,100 shares of company stock valued at $150,232. Corporate insiders own 14.78% of the company’s stock.

Institutional Investors Weigh In On Rezolute

Several institutional investors and hedge funds have recently made changes to their positions in RZLT. New York State Common Retirement Fund increased its position in shares of Rezolute by 5.6% during the 3rd quarter. New York State Common Retirement Fund now owns 24,600 shares of the company’s stock worth $231,000 after purchasing an additional 1,300 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Rezolute by 5.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,201 shares of the company’s stock worth $312,000 after acquiring an additional 1,567 shares in the last quarter. Pale Fire Capital SE grew its position in Rezolute by 4.2% during the 2nd quarter. Pale Fire Capital SE now owns 49,122 shares of the company’s stock worth $219,000 after acquiring an additional 2,000 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Rezolute by 5.5% during the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,659 shares of the company’s stock valued at $363,000 after purchasing an additional 2,014 shares in the last quarter. Finally, Huntleigh Advisors Inc. increased its holdings in Rezolute by 16.7% during the 3rd quarter. Huntleigh Advisors Inc. now owns 17,500 shares of the company’s stock valued at $164,000 after purchasing an additional 2,500 shares in the last quarter. Institutional investors and hedge funds own 82.97% of the company’s stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.